

Geisinger

Geisinger IRB Member Orientation – Session 2

Debra L. Henninger, MHS RN CCRC Associate Director, Research Compliance

How does the IRB make decisions?

Guiding Ethical Principles

Regulatory Considerations

Geisinger Policies




How does the IRB make decisions?


Guiding Ethical Principles

Regulatory Considerations

Geisinger Policies







Belmont Principles & Applications

RESPECT FOR PERSONS

Treat
individuals as
autonomous
agents +
protect those
with
diminished
autonomy

Obtain voluntary informed consent

BENEFICENCE

Maximize benefits; minimize risks of harm

Systematically analyze risks and benefits; minimize risks

JUSTICE

Distribute benefits and burdens of research fairly

Select subjects fairly; distribute benefits and burdens of research fairly



Author: F. Daniel Davis, PhD, 2016


How does the IRB make decisions?

Guiding Ethical Principles

Regulatory Considerations

Geisinger Policies





BELMONT PRINCIPLES	APPLICATIONS	COMMON RULE (HHS) 45 CFR 46
Respect for persons	Informed consent Information Comprehension Voluntariness	46.116: informed consent requirements 46.117: informed consent documentation
Beneficence	Risk-benefit assessment	46.111(a)(1): risks are minimized 46.111(a)(2): risks are reasonable in relationship to benefits 46.111(a)(6): safety monitoring 46.111(a)(7): privacy & confidentiality
Justice	Selection of subjects	46/111(a)(3): equitable selection of subjects 46.111(b): additional safeguards for vulnerable populations

Geisinger

What criteria must be met for research to be approved?



Risks to participants are reasonable

- ✓ ... in relation to anticipated benefits, if any, to subjects
- ... and the importance of the knowledge that may reasonably be expected to result

Consider ONLY those risks and benefits that may result form the research ... as distinguished from the therapies participants would receive even if not taking part in the research.



Risks to subjects are minimized

By using procedures ...

- ✓ consistent with sound research design
- ✓ that do not unnecessarily expose participants to risk
- ✓ already being performed on the participants for diagnostic or treatment purposes, when appropriate



Risks to subjects are minimized

Research proposal ...

- ✓ Addresses likelihood of harm and magnitude of harm
 - Potential physical, psychological, social and/or economic risks to participants
- ✓ Research is likely to achieve its proposed aims

✓ The importance of the knowledge expected to result is clear


Risks to subjects are minimized

- ✓ Any potential conflicts of interest are minimized or managed
 - ✓ Management plan (disclosure in consent; limits who can obtain consent, etc.)
- ✓ Credentials and/or qualifications of investigators and research staff are
 appropriate to perform their responsibilities in the study
- ✓ The research setting supports adequate safeguards for protection of participants
 - ✓ Location of research
 - √ Facilities
 - ✓ Drug/device controls & accounting



Selection of subjects is equitable, taking into account ...

- ✓ Purposes of the research
- ✓ Setting in which the research will take place
- ✓ Recruitment methods & participant payments
- ✓ Inclusion/exclusion criteria
- ✓ Special problems of research involving vulnerable populations




Informed consent will be sought from each prospective participant or his/her legally authorized representative (LAR)

- ✓ Adequate plans for seeking informed consent
- ✓ Proposed consent process
 - ✓ Provides participants/ participant's LAR with sufficient opportunity to consider whether to participate
 - ✓ Adequate information
 - ✓ Adequate time
 - ✓ Minimizes possibility of coercion or undue influence
- ✓ Information relayed during consent process
 - ✓ Is understandable language, comprehension
 - ✓ Does not include exculpatory language that appears to:
 - ✓ Waive any of participant's legal rights
 - ✓ Release the investigator, sponsor, institution from liability or negligence



Informed consent will be sought from each prospective participant or his/her legally authorized representative (LAR)





Informed consent will be appropriately documented

... in accordance with, and ... to the extent required by federal regulations

Study includes plan for monitoring data to ensure participant safety

- ✓ When study is greater than minimal risk
- ✓ When NIH-funded clinical research
- ✓ When FDA-regulated clinical trial



Study includes plan for monitoring data to ensure participant safety

Consider:

- ✓ Is plan appropriate for nature, size, complexity of research and degree of risk?
- ✓ Include plan for promptly detecting harm & mitigating potential injuries?
- ✓ What safety information is collected? How collect? How often?
- ✓ What data will be monitored & who will monitor?
- ✓ What is frequency of review or analysis of cumulative safety data to determine whether harm is occurring?
- ✓ Are there procedures for ensuring appropriate reporting of findings to IRB?
- ✓ Are there any conditions/criteria that could trigger immediate suspension/termination of research & procedures for reporting same?
- ✓ Is establishment of independent data safety monitoring board (DSMB) warranted? If so, is there a plan for providing DSMB reports to IRB?



Study includes adequate provisions to

... protect privacy of participants

- ✓ How are potential participants identified & contacted?
- ✓ Where is consent obtained? Where do study activities take place?


... maintain confidentiality of data

- ✓ Data elements? Data sources? Who obtains data? How?
- ✓ Where & how is data stored? When & how destroyed?
- ✓ How is data transported?
- ✓ Is data disclosed outside of Geisinger?
 - ✓ Is data transferred and stored securely? Encryption?



Where any of the participants are likely to be vulnerable to coercion or undue influence ...


...additional safeguards have been included in the study to protect participants





IRB must determine that ALL criteria are met prior to Issuing IRB approval

HIPAA Privacy Rule – Geisinger is a covered entity



HIPAA Identifiers

•Name	•Account Numbers
•Street address, city, county, precinct, zipcode	•Certificate/license numbers
•Dates	Vehicle identifiers and serial numbers
•Telephone Number	•Device identifiers and serial numbes
•Fax Number	•Web addresses (URL)
•Electronic mail address	•Internet addresses (IP)
Social Security Number	Biometric identifiers including fingerprints and voiceprints
•Medical record number	•Full face photographic images and comparable images
•Health plan identification numbers	•Any other unique identifying number, characteristic or code
	24



Use vs. Disclosure of PHI

Use: accessing, using, or sharing of PHI within Geisinger

Disclosure: the sharing of PHI outside of Geisinger (i.e., with another institution or even with Geisinger Health Plan)

HIPAA Regulations

Outside of treatment, payment and healthcare operations (TPO), the *permitted* use and disclosure of PHI requires:

PHI
Personal
Health
Information

	Use	Disclosure	Accounting for Disclosure
Authorization	$\sqrt{}$	\checkmark	
Waiver of authorization	\checkmark	$\sqrt{}$	$\sqrt{}$
De-identified			
Review Preparatory to Research	$\sqrt{}$		
Decedent Research	$\sqrt{}$		





How does the IRB make decisions?

Guiding Ethical Principles Regulatory Considerations Geisinger Policies



Institutional Requirements for IRB submissions

- ✓ Research Education requirements
- ✓ Research Financial Conflict of Interest requirements
- ✓ Principal Investigator requirements
- ✓ MCA & Billing Determination
- ✓ Investigational Pharmacy
- ✓ Radiation Safety Committee
- ✓ Institutional Biosafety Committee
- ✓ Information Security Office (ISO)
- ✓ Clinic/Provider/External Institution Approval for Recruitment
- ✓ Psychiatry Review for use of mental health data with identifiers
- ✓ Nurse Research Council (nurse researchers)
- ✓ MyCode Governing Board (use of MyCode data/samples)
- ✓ Geisinger Health Plan Proposal (use of GHP data)



Objectives

Human Research Protection Program & IRB Resources



Research > HRPP > <u>Human Research Protection Program</u>



Human Research Protection Program



Geisinger's Human Research Protection Program (HRPP), integrates the activities and functions of Geisinger Institutional Review Board (IRB), Office of Research Compliance (ORC), Office of Sponsored Projects (OSP), and other review units through oversight, education and quality assurance activities, including program administration. The HRPP seeks to assure the rights and welfare of research participants and promote excellence in all aspects of human subjects research.


Geisinger's HRPP has been successful in obtaining accreditation by the <u>Association for the Accreditation of Human Research Protection Programs (AAHRPP)</u>. Geisinger Health System was awarded the status of full accreditation for a three-year period, effective March 2016. This important achievement reflects Geisinger's commitment to protecting the rights and welfare of research participants.

Conflict of Interest / Education / Training	IRB Information		
Study Staff IRB Requirements Conflict of Interest – COI Human Research Education CITI	IRB Fees IRB 2016 & 2017 Submission Deadlines and Meeting Dates Staff listing		
Applying to the IRB via iRIS	Guides to Initiate Your Research		
Click here to access iRIS iRIS Site Access Request Form IRB submission checklist	Geisinger Research Process Flow Geisinger's Research Process Presentations		

HRPP Webpage



Geisinger Research Process Flow



Geisinger IRB Information

NAME: Geisinger Institutional Review Board

IRB REGISTRATION #: 00008345

INSTITUTION: Geisinger Clinic

FWA ASSURANCE: FWA00000063

ACCREDITATION: Geisinger Health System is accredited by the

Association for the Accreditation of Human

Protection Programs, Inc. (AAHRPP)

ADDRESS: Geisinger Institutional Review Board

100 North Academy Avenue

Danville, PA 17822-3069

TELEPHONE: 570-271-8663 or 844-542-3299

Geisinger

Contacts

- Barb Kent, Administrative Assistant (570) 271-8663
 - (bkent@geisinger.edu)
- Chuck Brightbill, MS, IRB Specialist
 - (cebright@geisinger.edu)
- Gissel Martinez, BS, IRB Specialist
 - > (gnmartinez@geisinger.edu)
- Rosa Sober, BS, CIP, IRB Manager
 - > (<u>rmsober@geisinger.edu</u>)
- Jeanie Wesner CCRC CHRC, IRB Project Manager
 - > (<u>jwesner@geisinger.edu</u>)
- Deb Henninger, MHSA RN CCRC, Associate Director
 - > (dhenninger@geisinger.edu)
- Les Kirchner, PhD, IRB Chair
 - hlkirchner@geisinger.edu
- Tom Challman, MD, IRB Chair
 - > tdchallman@geisinger.edu



QUESTIONS??

